Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis.
Oxagen Ltd., 91 Milton Park, Abingdon, Oxon OX14 4RY, UK. r.pettipher@oxagen.co.uk
Roy
R
Pettipher
Mark
M
Whittaker
D000085:Acetates / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D001372:Aza Compounds / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002227:Carbazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007210:Indoleacetic Acids / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011720:Pyrazoles / Q000737:chemistry / Q000627:therapeutic use; D011743:Pyrimidines / Q000737:chemistry / Q000627:therapeutic use; D011758:Pyrroles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D013449:Sulfonamides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D018418:Th2 Cells / Q000378:metabolism*; D013844:Thiazoles / Q000737:chemistry / Q000627:therapeutic use
D000085:Acetates; D001372:Aza Compounds; D002227:Carbazoles; D007210:Indoleacetic Acids; D011720:Pyrazoles; D011743:Pyrimidines; D011758:Pyrroles; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D013449:Sulfonamides; D013844:Thiazoles; C521801:thienopyrrole; C063119:ramatroban; C036293:prostaglandin D2 receptor